Drug Trials Snapshots: REZDIFFRA | FDA
...The FDA approved REZDIFFRA based on evidence of efficacy from a clinical trial, Trial 1, of 888 patients who had a liver biopsy showing inflammation due to NASH with moderate or advanced......
https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rezdiffra
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra ...
...Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as ?MASH?) Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved liver fibrosis and resolved NASH in patients with noncirrhotic NASH with moderate to advanced liver fibrosis...
https://www.madrigalpharma.com/wp-content/uploads/2024/03/Approval-Press-Release-FINAL.pdf
Estimation of the Eligible Population For Resmetirom Among ... - Springer
...Estimates of the diagnosed, treatment-eligible NASH population are poorly understood due to diagnostic variability. This study provides a contemporary estimate of the size of the US res- metirom treatment-eligible population....
https://link.springer.com/content/pdf/10.1007/s12325-024-02989-5.pdf
FDA Accelerated Approval for Madrigal?s Rezdiffra? in Win for NASH Patients
...This represents the first and only drug to be approved for NASH, an advanced liver disease and a leading cause of liver-related mortality, that affects between 1.5% and 6.5% of the US adult population....
https://prismmarketview.com/fda-accelerated-approval-for-madrigals-rezdiffra-in-win-for-nash-patients/
Resmetirom (Rezdiffra): Deep Dive into MAESTRO-NASH Data
...MAESTRO-NASH Phase 3 data for Resmetirom (first FDA-approved MASH drug, 2024): co-primary endpoints, subgroups, MRI-PDFF/LDL-C, GAN-DIO translation....
https://www.fibrosis-inflammation.com/en/insights/drug_resmetirom_clinical_details
Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment ...
...Madrigal estimates that approximately 1.5 million patients have been diagnosed with NASH in the U.S., of which approximately 525,000 have NASH with moderate to advanced liver fibrosis....
https://www.streetinsider.com/Corporate+News/Madrigal+Pharma+%28MDGL%29+Confirms+FDA+Approval+of+Rezdiffra+for+Treatment+of+Patients+with+Noncirrhotic+NASH+with+Moderate+to+Advanced+Liver+Fibrosis/22933126.html
FDA approves Madrigal?s Rezdiffra as first drug for fatty ... - PMLiVE
...Over six million people in the US are affected by NASH with moderate-to-advanced liver scarring...
https://pmlive.com/pharma_news/fda-approves-madrigals-rezdiffra-as-first-drug-for-fatty-liver-disease-nash/
New Drug Evaluation Monograph Template - orpdl.org
...There is limited data in non-White populations, patients with significantly uncontrolled (HbA1C ?9%) type 2 diabetes (T2D), who have Stage 1 or 4 NASH, or liver fibrosis from other causes. Implement prior authorization (PA) for resmetirom to ensure safe and appropriate use....
https://www.orpdl.org/durm/meetings/meetingdocs/2024_08_01/finals/Rezdiffra_NDE.pdf
What are the FDA-approved drugs for metabolic liver disease ...
...Resmetirom (REZDIFFRA) is currently the only FDA-approved drug for treating noncirrhotic NASH with moderate to advanced liver fibrosis (F2-F3), approved in 2......
https://www.droracle.ai/articles/585206/what-are-the-fda-approved-drugs-for-metabolic-liver-disease
FDA?s Approval of Breakthrough NASH Treatment Opens Door for a Long ...
...With researchers anticipating 27 million cases of NASH in the U.S. by 2030, we are thrilled with this FDA approval of the first-ever medication for NASH as another tool to treat a stage of this serious, progressive disease,? shared Jeff McIntyre, VP of Liver Health Programs at GLI....
https://www.einpresswire.com/article/696046755/fda-s-approval-of-breakthrough-nash-treatment-opens-door-for-a-long-neglected-patient-population